Advanced Magnetics disclaims any obligation to publicly update or revise any
such statements to reflect any change in expectations or in events, conditions
or circumstances on which any such statements may be based, or that may affect
the likelihood that actual results will differ from those set forth in the
forward-looking statements.

tecnet hacettepe

The
lawsuit, filed today in Massachusetts Superior Court, is in connection with
the license agreement established between Cytogen and Advanced Magnetics in
2000, as amended, for both Combidex(R) and ferumoxytol, previously Code 7228.
Documents posted on the FDA website include briefs submitted by Advanced
Magnetics and the FDA.

whos wsd

, Cytogen Corporation
(Nasdaq: CYTO) announced today that it has filed a lawsuit against Advanced
Magnetics, Inc. All
statements, other than statements of historical facts, included in this press
release regarding our strategy, future operations, financial position, future
revenues , projected costs, prospects, plans and objectives of management are
forward-looking statements.,
Advanced Magnetics, Inc. The briefing documents can be accessed at
http://www.S. As a result,
this press release should be read in conjunction with Cytogen's periodic
filings with the SEC .

samarium swri

Such forward-looking statements involve a number
of risks and uncertainties and investors are cautioned not to put any undue
reliance on any forward-looking statement.fda.

cetem hacettepe

htm.

wirs whos

cytogen.

FDA Posts Briefing Documents Related to March 3rd Oncologic Drugs Advisory Committee on COMBIDEX(R) (ferumoxtran-10)

cytogen.

For Advanced Magnetics
This document contains forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995 and federal securities
laws . Any statements contained in this press release that do not describe
historical facts are forward -looking statements that involve risks and
uncertainties that could cause actual results to differ materially from those
discussed in such forward-looking statements.

elevate wsda

For more information about Advanced
Magnetics, please visit the company's website at
http://www.

itac hacettepe

ABOUT CYTOGEN CORPORATION
Founded in 1980, Cytogen Corporation of Princeton, NJ is a
biopharmaceutical company that acquires, develops and commercializes
innovative molecules targeting the sites and stages of cancer progression.cytogen.

About Advanced Magnetics
Advanced Magnetics, Inc.

wsd upm

There are a number of important
factors that could cause Cytogen's results to differ materially from those
indicated by such forward-looking statements. Cytogen's marketed products include QUADRAMET(R) (samarium Sm-153
lexidronam injection) and PROSTASCINT(R) (capromab pendetide) kit for the
preparation of Indium In-111 capromab pendetide in the United States.
Advanced Magnetics cautions readers not to place undue reliance on any
forward-looking statements which speak only as of the date they are made . In particular, Cytogen's
business is subject to a number of significant risks, which include, but are
not limited to: the risk of obtaining the necessary regulatory approvals; the
risk of whether products result from development activities; the risk of
shifts in the regulatory environment affecting sales of Cytogen's products
such as third-party payor reimbursement issues; the risk associated with
Cytogen's dependence on its partners for development of certain projects, as
well as other factors expressed from time to time in Cytogen's periodic
filings with the Securities and Exchange Commission (the "SEC").

publicizing whos

The forward-looking
statements contained herein are made only as of the date of this press
release, and Cytogen undertakes no obligation to publicly update such forward-
looking statements to reflect subsequent events or circumstances.

For Cytogen
This press release contains certain "forward-looking" statements within
the meaning of the Private Securities Litigation Reform Act of 1995 and
Section 21E of the Securities Exchange Act of 1934, as amended.

wirs samarium

com, which is not part of this press release.
For more information, please visit the Company's website at
http: //www. The forward-looking statements contained herein are made
only as of the date of this press release, and Cytogen undertakes no
obligation to publicly update such forward-looking statements to reflect
subsequent events or circumstances.

ife itac

com or by calling 1-800-833-3533.

yea ife

CAMBRIDGE , Mass. Such forward-looking statements
involve a number of risks and uncertainties and investors are cautioned not to
put any undue reliance on any forward-looking statement.

whos relavant

The complaint seeks damages along with a request for specific performance
requiring Advanced Magnetics to take all reasonable steps to secure FDA
approval of Combidex in compliance with the terms of the licensing agreement.

This press release contains certain "forward-looking" statements within
the meaning of the Private Securities Litigation Reform Act of 1995 and
Section 21E of the Securities Exchange Act of 1934, as amended.J. Food and Drug Administration (FDA) has posted on
its website briefing documents for the Oncologic Drugs Advisory Committee
(ODAC) meeting to be held March 3, 2005 relating to Combidex(R), Advanced
Magnetics' investigational functional molecular imaging agent .gov/ohrms/dockets/ac/05/briefing/2005-4095b1. As a leader in its field,
Advanced Magnetics is dedicated to the development and commercialization of
its proprietary nanoparticle technology for use in therapeutic iron compounds
to treat anemia, as well as novel imaging agents to aid in the diagnosis of
cardiovascular disease and cancer. Food and Drug
Administration.

wsd cetem

(AMEX: AVMCYTO)
announced today that the U.cytogen .

swri upm

Cytogen Files Breach of Contract Lawsuit Against Advanced Magnetics Inc.

PRINCETON, N.

wsd pacon

J. (Amex: AVM) for breach of contract, fraud, unjust enrichment,
and breach of the implied covenant of good faith and fair dealing.advancedmagnetics. COMBIDEX, an investigational molecular imaging agent consisting of
iron oxide nanoparticles, is currently being developed for use in conjunction
with magnetic resonance imaging to aid in the differentiation of cancerous and
non-cancerous lymph nodes, and is under review by the U.

yea upm

com, the content of which is not part of this
press release.com, which is not part of this press release.

ifia wirs

Combidex is an investigational functional molecular imaging agent consisting
of iron oxide nanoparticles for use in conjunction with magnetic resonance
imaging, or MRI, to aid in the differentiation of cancerous from non-cancerous
lymph nodes. As a result, this press release should be read in
conjunction with Cytogen's periodic filings with the SEC. and Princeton, N. Cytogen 's development pipeline consists of therapeutics
targeting prostate-specific membrane antigen (PSMA ), a protein highly
expressed on the surface of prostate cancer cells and the neovasculature of
solid tumors. Such risks and uncertainties
include the following: (1) that the FDA advisory committee does not recommend
approval, or delays the recommendation of approval, of Combidex; (2) the
convening and recommendation of an FDA advisory committee does not ensure
approval or disapproval of Combidex; (3) the possibility that the division of
medical imaging may not agree with the recommendations of the ODAC; (4) the
possibility that even though Advanced Magnetics' response regarding Combidex
was deemed complete by the FDA, the FDA could respond to this submission by
issuing an additional approvable letter with additional conditions for
approval or the FDA could issue a not approvable letter; (5 ) the ability to
resolve final labeling for Combidex with the FDA; (6) the possibility that
even though the FDA has assigned a user fee goal date of March 30, 2005, the
FDA may not act by such date; (7) uncertainties regarding market acceptance of
Combidex; (8) uncertainties relating to third-party reimbursements to Advanced
Magnetics or its partners for Combidex when patients are prescribed Combidex;
(9) uncertainties relating to Advanced Magnetics' ability to continue to
operate at commercial scale in compliance with FDA regulations and other
applicable manufacturing requirements when producing Combidex; (10)
uncertainties relating to patents and proprietary rights and (11) other risks
identified in Advanced Magnetics' Securities and Exchange Commission filings.

publicizing samarium

Cytogen stated that it remains interested in discussing with Advanced
Magnetics an amicable resolution of Cytogen's complaints.

serviceclub mim

Cytogen's marketed products include QUADRAMET(R) (samarium Sm-153 lexidronam
injection) and PROSTASCINT (R) (capromab pendetide) kit for the preparation of
Indium In-111 capromab pendetide in the United States.
Cytogen's development pipeline consists of therapeutics targeting prostate-
specific membrane antigen (PSMA), a protein highly expressed on the surface of
prostate cancer cells and the neovasculature of solid tumors. In particular, Cytogen's
business is subject to a number of significant risks, which include, but are
not limited to: the risk of successfully pursuing the Advanced Magnetics
litigation; the risk of obtaining additional capital; the risk of obtaining
the necessary regulatory approvals; the risk of whether products result from
development activities; the risk of shifts in the regulatory environment
affecting sales of Cytogen's products such as third-party payor reimbursement
issues; the risk associated with Cytogen's dependence on its partners for
development of certain projects , as well as other factors expressed from time
to time in Cytogen's periodic filings with the Securities and Exchange
Commission (the "SEC"). is a developer of superparamagnetic iron oxide
nanoparticles used in pharmaceutical products.

yea swri

ife pacon

Cytogen also has
exclusive United States marketing rights to Combidex (R) (ferumoxtran-10) for
all applications, and the exclusive right to market and sell ferumoxytol
(previously Code 7228) for oncology applications in the United States.
Clinical studies have shown that Combidex is taken up by macrophages in normal
lymph node tissue, which aids clinicians in differentiating between normal and
cancerous lymph nodes when using MRI. There are a number of
important factors that could cause Cytogen's results to differ materially from
those indicated by such forward-looking statements.

pacon upm

However, Cytogen
intends to protect its rights whether through litigation or negotiation . Full prescribing
information for the Company's products is available at http://www.com
or by calling 800-833-3533.

About Cytogen Corporation
Founded in 1980, Cytogen Corporation of Princeton, NJ is a product-driven
biopharmaceutical company that develops and commercializes innovative
molecules that can be used to build leading franchises across multiple
markets. Cytogen
also has exclusive United States marketing rights to COMBIDEX(R) (ferumoxtran-
10) for all applications , and the exclusive right to market and sell
ferumoxytol (previously Code 7228) for oncology applications in the United
States. All
statements, other than statements of historical facts, included in this press
release regarding Cytogen's strategy, future operations, financial position,
future revenues , projected costs, prospects, plans and objectives of
management are forward-looking statements.

wsda relavant

For more information, please visit the Company's
website at http://www.S.
Combidex (ferumoxtran -10) consists of iron oxide nanoparticles for use in
conjunction with magnetic resonance imaging (MRI) to image lymph nodes. Full prescribing information for the Company's products is
available at http://www.